Special Issue "Supportive and Palliative Cancer Treatment"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: 30 November 2020.
Interests: palliative care; complementary medicine; cannabis research; immunotherapy; skin cancers; sarcoma
Modern medicine has brought about an increase in the life expectancy of a significant number of patients with advanced cancer. Almost all international oncology groups recommend that combined standard oncology care and palliative care should be considered early in the course of the illness for any patient with metastatic cancer and/or a high symptom burden. However, a gap exists between this recommendation and current practice.
Supportive care is mainly related to improving quality of life during oncology treatments, including surgery, radiotherapy, and adjuvant chemo- or immunotherapy. Taken together, supportive and palliative care, with its focus on management of symptoms care, psychosocial support, and assistance with decision-making, has the potential to improve quality of life, prolong survival, and reduce use of medical services.
The journal Pharmaceuticals invites both reviews and original articles that shed light on the challenges and opportunities of using different drugs, natural products, and a specific nutritional diet for symptom control and reducing oncology treatment side effects in cancer patients. Basic studies that provide hints for future applications in supportive oncology care are also welcome. The collection of manuscripts will be published as a Special Issue of the journal.
Prof. Gil Bar-Sela
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- palliative care
- supportive care
- complementary medicine
- Treatment Options and Therapeutics for Non-small Cell Lung Cancer in Pharmaceuticals
- New Therapies for Hepatocellular Carcinoma in Pharmaceuticals
- Novel Therapeutic Targets in Cancer in Pharmaceuticals (1 article)
- Malignant Glioma: Novel Therapeutic Strategies in Pharmaceuticals
- Cancer Translational Biomarkers and Targeted Therapies in Pharmaceuticals
- Clinical Development of Cancer Treatment in Pharmaceuticals
- Anticancer Drugs in Pharmaceuticals (10 articles)